Greenland Mines Ltd

What they do

The company operates two segments: Biotech, which holds a portfolio of off-patent generic drugs and biosimilar antibodies licensed from Reliance Life Sciences, plus a pre-clinical gene therapy program for the Klotho protein; and Mining, which explores and develops critical and precious minerals at the Skaergaard Project in eastern Greenland. It also owns market-approved anti-cancer drugs (FOLFOX/FOLFIRI regimens) for sale in Germany.

Revenue drivers

• Generic drug portfolio (Germany) — Five market-approved anti-cancer drugs acquired in September 2022, including FOLFOX/FOLFIRI regimens and lung cancer treatments; generates sales from German market authorizations.
• Biosimilar biologics (Reliance Life Sciences) — Two off-patent bio generic antibodies in-licensed from RLS; potential revenue from biosimilar sales, though not yet commercialized.
• Klotho gene therapy — Pre-clinical stage program in-licensed from UAB; no revenue yet, but potential high-reward opportunity if developed.
• Mining segment (Skaergaard Project) — Acquired via Greenland Mines Corp. in March 2026; represents a new revenue driver from mineral exploration and development, though early stage.

Recent performance

Net losses widened from $6.2M in 2024 to $10.6M in 2025, with operating cash flow of -$5.9M in 2025. As of March 31, 2026, total assets were $59.7M, cash was $10.0M, and shareholder equity was $51.5M. No revenue figures were provided in the excerpts; the company has not yet demonstrated profitability.

Strategy

Management is executing a strategic pivot: the March 2026 acquisition of Greenland Mines Corp. adds a mining segment and the Skaergaard Project, while retaining the biotech platform. The company plans to advance its Klotho gene therapy and biosimilar portfolio, potentially through partnerships or out-licensing, and to allocate future capital toward mining development. There is no stated commitment to maintain the biotech operations at current levels.

Risks

• Significant losses and funding needs — The company has incurred net losses in 2023-2025 and expects to continue losing money, requiring substantial additional funding to meet obligations.
• Pre-clinical gene therapy risk — Klotho gene therapy is pre-clinical, may never receive approval, and faces regulatory and public opinion scrutiny regarding gene therapy.
• Mining exploration risk — The Skaergaard Project is an exploration-stage asset; mineral development is capital-intensive and subject to geological, regulatory, and market risks.
• Competition in biosimilars and mining — The company faces significant competition in biosimilars and mineral exploration, which could impact commercial viability.

Outlook

Management did not provide specific forward-looking guidance in the excerpts. The company expects to continue incurring losses over the next several years and will need additional funding. The strategic focus is on the new mining segment while the biotech pipeline remains a longer-term, higher-risk opportunity.